Astrana Health Inc.

Greetings, and welcome to the Apollo Medical Holdings fourth quarter and year-end 2020 financial results conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If you would like to ask a question, you may press star 1 on your telephone keypad in order to enter the question queue. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Carolyn Sohn. Thank you, Ms. Sohn.

Thank you, Operator, and hello, everyone. Thank you for joining us. The press release announcing Apollo Medical Holdings, Inc.'s results for the fourth quarter and year-ended December 31, 2020 is available at the Investors section of the company's website at www.apollomed.net. To provide some additional background on its results, the company has made a supplemental deck available on its website. A replay of this broadcast will also be made available at Apollo Med's website after the conclusion of this call. Before we get started, I would like to remind everyone that this conference call and any accompanying information discussed herein contains certain forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terms such as anticipate, believe, expect, future, plan, outlook, and will, and include, among other things, statements regarding the company's guidance for the year ending December 31, 2021, continued growth, acquisition strategy, ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth plans, and Merger Integration Efforts, as well as the impact of the 2020 novel coronavirus COVID-19 pandemic on the company's business, operations and financial results. Although the company believes that the expectations reflected in its forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties that could cause the actual results to differ dramatically from those projected. There can be no assurance that those expectations will prove to be correct. Information about the risks associated with investing in ApolloMed is included in filings with the Securities and Exchange Commission, which we encourage you to review before making an investment decision. The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions, or otherwise, except as required by law. Regarding the disclaimer language, I would also like to refer you to slide two of the conference call presentation for further information. For those of you following along with the In-Company PowerPoint presentation, there is an overview of the company on slide three. On today's call, the company's executive chairman and co-CEO, Dr. Kenneth Sim, will provide an overview of 2020 annual highlights, as well as those for the fourth quarter. The company's chief operating officer and chief technology officer, Brandon Sim, will then discuss the latest operational developments, and chief financial officer, Eric Chin, will follow with a review of ApolloMed's results for full year 2020. Brandon will conclude the remarks with a discussion of the company's outlook, as well as its long-term growth strategy, before opening the floor for questions. With that, I'll turn the call over to Apollo Med's executive chairman and co-CEO, Dr. Kenneth Sim. Please go ahead, Dr. Sim.

Thank you. Good afternoon to all of you, and thank you for joining us to discuss Apollo Med's fourth quarter and year-end 2020 results, particularly as this is the company's first earnings call. We look forward to maintaining this dialogue with the investment community in the quarters to come. I'm here today with Brandon, our COO and CTO, and Eric, our CFO. We are pleased to have this opportunity to speak with you all today, particularly as we come off a year of unprecedented circumstances brought on by the COVID-19 pandemic. To that end, I would like to begin by expressing my gratitude to our network of healthcare providers and their support staff for their unwavering commitment over the course of the past year. The heroic work being done by so many of our affiliated physicians and partners to help test for, treat, prevent, and vaccinate against COVID-19 is truly profound and inspiring. With the help of everyone within our organization, we continue to do everything that we can to make sure our members are receiving the highest quality, the most cost-efficient care they've come to associate with ApolloMed. Since this is our first earnings call, we wanted to take a moment to answer the question, what does ApolloMed do and how are we Thank you, Dr. Sim. To summarize, ApolloMed is a physician-centric, technology-powered, risk-bearing healthcare management and delivery company focused on operating an integrated value-based care model.